Precision Business Insights has published a report on the global duchenne muscular dystrophy treatment market, estimating its value at USD 5.3 billion in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 38.2% over the forecast period 2025-2031. The report explores the market growth and potential opportunities in the market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.
View the detailed report description here -https://www.precisionbusinessinsights.com/market-reports/global-duchenne-muscular-dystrophy-treatment-market
The duchenne muscular dystrophy (dmd) treatment market encompasses all the therapeutic options, drugs, assistive devices, gene therapies, and supportive care services developed to manage and treat DMD, a severe form of muscular dystrophy caused by mutations in the DMD gene. This market focuses on interventions aimed at slowing disease progression, improving muscle function, enhancing quality of life, and extending the lifespan of patients with DMD. It includes pharmacological therapies, gene editing techniques, physical therapy, and emerging precision medicines.
Drivers:
- Growing Prevalence of DMD: Increasing diagnosis rates and improved genetic screening have led to a growing patient population worldwide.
- Advancements in Gene Therapy: Breakthroughs in CRISPR and other gene-editing technologies are driving significant investment and clinical trials for potentially curative treatments.
The global duchenne muscular dystrophy treatment market segmentation:
- By Drug Class: Corticosteroids, Pain management drugs
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=17193
Regional Overview:
The report also examines the current concerns and their Future Effects on the duchenne muscular dystrophy treatment market by the region. The report covers all regions and countries, North America was the largest and Asia was the fastest-growing region in the duchenne muscular dystrophy treatment market. The market has been segmented into numerous primary regions and a detailed evaluation of primary countries.
- North America (U.S., Canada)
- Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
- Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
- Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)
The competitive landscape is dominated by major players like Bristol-Myers Squibb (U.S), FibroGen, Inc. (U.S), ITALFARMACO S.p.A. (Italy), Catabasis Pharmaceuticals, Inc. (U.S), NS Pharma, Inc. (U.S), Marathon Pharmaceuticals, LLC (U.S), ReveraGen BioPharma, Inc. (U.S), Pfizer (U.S), Summit Therapeutics plc (U.K), Taiho Pharmaceutical Co. (Japan), Sarepta Therapeutics, Inc. (U.S), Santhera Pharmaceuticals, PTC Therapeutics (Switzerland).
About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.
Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.
Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747
